The interplay between microbiota‐dependent metabolite trimethylamine <i>N</i>‐oxide, Transforming growth factor <i>β</i>/SMAD signaling and inflammasome activation in chronic kidney disease patients: A new mechanistic perspective

Abstract

The study documented that TMAO could be used as a reliable biomarker to evaluate CKD progression; being linked to TGF-β/SMAD signaling, NLRP3 inflammasome activation as well as being a noninvasive applicable technique.